Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Review, H1 2016

  • ID: 3802731
  • Drug Pipelines
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Xention Limited
  • MORE
Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Review, H1 2016

Summary

‘Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Review, H1 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5)
- The report reviews Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Xention Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Overview

Therapeutics Development

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Products under Development by Stage of Development

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Products under Development by Therapy Area

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Products under Development by Indication

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Products under Development by Companies

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Products under Development by Universities/Institutes

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Bristol-Myers Squibb Company

Laboratoires Pierre Fabre SA

Xention Limited

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Drug Profiles

AFC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-919373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-373280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEND-0103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Dormant Projects

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Discontinued Products

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Featured News & Press Releases

Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation

Mar 20, 2012: Xention Reports Positive Phase I Data For New Atrial Fibrillation Drug

Jul 27, 2011: Xention Initiates Phase I Clinical Trial Of XEN-D0103

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 36List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Laboratoires Pierre Fabre SA, H1 2016

Pipeline by Xention Limited, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 32List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Xention Limited
  • MORE
Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) Potassium voltage-gated channel subfamily A member 4 or Kv1.4 is a protein encoded by the KCNA4 gene. It mediates transmembrane potassium transport in excitable membranes. Its functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume.

Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

The author's latest report Potassium Voltage Gated Channel Subfamily A Member 5 - Pipeline Review, H1 2016, outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
AstraZeneca Plc
Bristol-Myers Squibb Company
Laboratoires Pierre Fabre SA
Xention Limited
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll